

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is for information purposes only and does not constitute an invitation or solicitation of an offer to acquire, purchase or subscribe for securities of the Company or an invitation to enter into an agreement to do any such things, nor is it calculated to invite any offer to acquire, purchase or subscribe for any securities of the Company.*

*This announcement and the information herein is not for distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement and the information herein does not constitute or form a part of any offer or solicitation to purchase, subscribe or sell securities in the United States. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the “**U.S. Securities Act**”), or the securities laws of any state of the United States or other jurisdiction. The securities referred to herein are being offered and sold outside the United States in reliance on Regulation S under the U.S. Securities Act (the “**Regulation S**”) and may not be offered or sold within the United States absent registration or an applicable exemption from registration under the U.S. Securities Act. No public offering of the securities referred to herein will be made in the United States or in any other jurisdiction where such an offering is restricted or prohibited. No money, securities or other consideration is being solicited by this announcement or the information contained herein and, if sent in response to this announcement or the information contained herein, will not be accepted.*



## **Hansoh Pharmaceutical Group Company Limited**

**翰森製藥集團有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 3692)**

### **PROPOSED ISSUE OF HK\$4,680 MILLION ZERO COUPON CONVERTIBLE BONDS DUE 2033**

**Joint Global Coordinators and Joint Bookrunners**

**Morgan Stanley**



#### **PROPOSED ISSUANCE OF CONVERTIBLE BONDS**

The Board is pleased to announce that on January 26, 2026 (after trading hours), the Company and the Managers entered into the Subscription Agreement. Pursuant to the Subscription Agreement, among other things, the Company has conditionally agreed to issue to the Managers or as they may direct, and the Managers have conditionally agreed with the Company to severally and not jointly subscribe and pay for, the Bonds, subject to certain conditions set out in the Subscription Agreement.

The Bonds may be converted into Conversion Shares pursuant to the Terms and Conditions. Assuming full conversion of the Bonds at the initial Conversion Price of HK\$57.39 per Share and no further issue of Shares, the Bonds will be convertible into 81,547,308 Shares (with aggregate nominal value of approximately HK\$815), representing approximately 1.35% of the issued share capital of the Company as at the date of this announcement and approximately 1.33% of the issued share capital of the Company as at the date of this announcement as enlarged by the issue of the Conversion Shares upon full conversion of the Bonds. The Conversion Shares to be issued upon conversion of the Bonds will rank *pari passu* and carry the same rights and privileges in all respects with the Shares then in issue on the relevant registration date.

The Bonds have not been offered or sold and may not be offered or sold in Hong Kong to the public within the meaning of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32). The Bonds will be offered by way of debt issue to professional investors only.

The Bonds and the Conversion Shares have not been and will not be registered under the U.S. Securities Act or the securities laws of any state of the United States and no public offering will be made in the United States. Neither the Bonds nor the Conversion Shares may be offered or sold within the United States absent registration under, or an applicable exemption from, or in a transaction not subject to, the registration requirements under the U.S. Securities Act and applicable state or local securities laws of the United States. The Bonds are being offered, sold or delivered outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.

The net proceeds from the Bonds (after deduction of commissions and other related expenses) are estimated to be approximately HK\$4,640 million, representing a net issue price of approximately HK\$56.90 per Conversion Share based on the initial Conversion Price. The Group intends to apply the net proceeds from the issue of the Bonds in the manner detailed in the section headed “Use of Proceeds”.

The Conversion Shares will be allotted and issued under the General Mandate. As such, the issue of the Conversion Shares is not subject to additional approval of the Shareholders.

An application will be made to the Vienna MTF operated by the Vienna Stock Exchange for the listing of, and permission to deal in, the Bonds. The Company will also apply to the Stock Exchange for the listing of, and permission to deal in, the Conversion Shares on the Stock Exchange.

**Completion of the transactions under the Subscription Agreement is subject to the satisfaction and/or waiver of certain conditions precedent therein. As the issue of the Bonds under the Subscription Agreement may or may not proceed to completion, and the Bonds and/or the Conversion Shares may or may not be issued or listed, Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.**

## **INTRODUCTION**

The Board is pleased to announce that on January 26, 2026 (after trading hours), the Company and the Managers entered into the Subscription Agreement.

## **SUBSCRIPTION AGREEMENT**

Date: January 26, 2026 (after trading hours)

Parties: (1) the Company, as the issuer; and  
(2) the Managers.

To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, each of the Managers and its respective ultimate beneficial owner is a third party independent of the Company and is not a connected person of the Company.

### **Subscription**

The Company has conditionally agreed to issue to the Managers or as they may direct, and the Managers have conditionally agreed with the Company to severally and not jointly subscribe and pay for, the Bonds on the Closing Date.

### **Subscribers**

The Managers have informed the Company that the Bonds will be offered and sold to no less than six independent placees (who will be professional investors).

To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, each of the initial placees (and their respective ultimate beneficial owners) is a third party independent of the Company and is not a connected person of the Company.

## Conditions Precedent to the Subscription Agreement

The obligations of the Managers to subscribe and pay for the Bonds are conditional on:

- (a) **Due Diligence:** the Managers being satisfied with the results of their due diligence investigations with respect to the Group;
- (b) **Other Contracts:** the execution and delivery (on or before the Closing Date) of the other Contracts, each in a form satisfactory to the Managers, by the respective parties;
- (c) **Compliance:** at the Closing Date, the representations and warranties of the Company in the Subscription Agreement being true, accurate and correct at, and as if made on, such date, the Company having performed all of its obligations under the Contracts to be performed on or before such date, and there having been delivered to the Managers a certificate confirming no material adverse change and no default signed by a duly authorized officer of the Company in the form as agreed in the Subscription Agreement;
- (d) **Other Consents:** on or prior to the Closing Date, there shall have been delivered to the Managers copies of all consents and approvals required in relation to the issue of the Bonds and the performance of the Company's obligations under the Trust Deed, the Agency Agreement and the Bonds;
- (e) **Listing:** the Stock Exchange having agreed to list the Conversion Shares;
- (f) **NDRC Pre-Issuance Registration Certificate:** on or prior to the Closing Date, there having been delivered to the Managers a copy of the Registration Certificate of Foreign Debt Borrowed by Enterprise (企業借用外債審核登記證明) for the issue of the Bonds evidencing the registration of the issue of the Bonds with the NDRC; and
- (g) **Legal Opinions:** on or before the Closing Date, there having been delivered to the Managers opinions, in form and substance satisfactory to the Managers of certain legal opinions on the laws of various jurisdictions.

The Managers may, at their discretion and upon such terms as they think fit, waive compliance with the whole or any part of the above conditions (other than conditions (b) and (f) above).

As at the date of this announcement, not all of the above conditions have been satisfied and/or (as the case may be) waived. The Company is working towards the satisfaction of all of the above conditions by the Closing Date.

## **Termination**

The Managers may, by notice to the Company given at any time prior to payment of the net subscription monies for the Bonds to the Company, terminate the Subscription Agreement on the occurrence of customary termination events, including without limitation breach of certain representations, warranties and undertakings by the Company contained in the Subscription Agreement; if any of the conditions precedent specified in the Subscription Agreement has not been satisfied or waived by the Managers on or prior to the Closing Date and the occurrence of certain force majeure events.

## **LOCK-UP UNDERTAKINGS**

### **The Company**

The Company has undertaken with the Managers that neither the Company nor any person acting on its behalf will (a) issue, offer, sell, pledge, contract to sell or otherwise dispose of or grant options, issue warrants or offer rights entitling persons to subscribe or purchase any interest in any Shares or securities of the same class as the Bonds or the Shares or any securities convertible into, exchangeable for or which carry rights to subscribe or purchase the Bonds, the Shares or securities of the same class as the Bonds, the Shares or other instruments representing interests in the Bonds, the Shares or other securities of the same class as them; (b) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of the ownership of the Shares; (c) enter into any transaction with the same economic effect as, or which is designed to, or which may reasonably be expected to result in, or agree to do, any of the foregoing, whether any such transaction of the kind described in (a), (b) or (c) is to be settled by delivery of Shares or other securities, in cash or otherwise; or (d) announce or otherwise make public an intention to do any of the foregoing, in any such case without the prior written consent of the Managers between the date of the Subscription Agreement and the date which is 90 days after the Closing Date (both dates inclusive), except for (i) the issuance of the Bonds and the Conversion Shares; and (ii) any issuance of Shares under the Restricted Share Unit Scheme.

The lock-up undertaking of the Company will terminate if the Subscription Agreement is terminated in accordance with its terms.

## PRINCIPAL TERMS OF THE BONDS

The principal terms of the Bonds are summarized as follows:

Issuer:	the Company
Principal amount:	HK\$4,680 million
Issue Date:	February 3, 2026
Maturity Date:	February 3, 2033
Issue Price:	100.00 per cent. of the principal amount of the Bonds
Interest Rate:	The Bonds do not bear any interest
Default Interest:	The Bonds are zero coupon and do not bear interest unless, upon due presentation thereof, payment of principal is improperly withheld or refused. In such event, such unpaid amount shall bear interest at the rate of 1 per cent. per annum (both before and after judgment) until whichever is the earlier of (A) the day on which all sums due in respect of such Bond up to that day are received by or on behalf of the relevant holder, and (B) the day falling seven days after the trustee or the principal agent of the Bonds has notified Bondholders of receipt of all sums due in respect of all the Bonds up to that seventh day (except to the extent that there is failure in the subsequent payment to the relevant holders under these Conditions). If interest is required to be calculated for a period of less than one year, it will be calculated on the basis of a 360-day year consisting of twelve months of 30 days each and, in the case of an incomplete month, the number of days elapsed.
Form and Denomination:	The Bonds are in registered form in the denomination of HK\$2,000,000 and integral multiples of HK\$1,000,000 in excess thereof. Upon issue, the Bonds will be represented by a global certificate registered in the name of a nominee of, and deposited with a common depositary for Euroclear Bank SA/NV and Clearstream Banking, S.A.
Status:	The Bonds constitute direct, unconditional, unsubordinated and subject to the Terms and Conditions, unsecured obligations of the Company and shall at all times rank <i>pari passu</i> and without any preference or priority among themselves. The payment obligations of the Company under the Bonds shall, save for such exceptions as may be provided by mandatory provisions of applicable law and subject to the Terms and Conditions, at all times rank at least equally with all of its other present and future unsecured and unsubordinated obligations.

Conversion Right:

Subject to and upon compliance with the Terms and Conditions, the conversion right in respect of a Bond may be exercised, at the option of the Bondholder, at any time (subject to any applicable fiscal or other laws or regulations and as provided in the Terms and Conditions) on or after March 16, 2026 up to the close of business (at the place where the certificate evidencing such Bond is deposited for conversion) on the date falling ten days prior to the Maturity Date (both days inclusive) (but, except as provided in the Terms and Conditions, in no event thereafter), or if such Bond shall have been called for redemption by the Company before the Maturity Date, then up to the close of business (at the place aforesaid) on a date no later than ten days (both days inclusive and in the place aforesaid) prior to the date fixed for redemption thereof, or if notice requiring redemption has been given by the Bondholder pursuant to the Terms and Conditions, then up to the close of business (at the place aforesaid) on the day prior to the giving of such notice.

The number of Conversion Shares to be issued on exercise of a conversion right shall be determined by dividing the principal amount of the Bonds to be converted by the Conversion Price in effect on the relevant Conversion Date (as defined in the Terms and Conditions).

Conversion Price:

The initial Conversion Price is HK\$57.39 per Share.

The Conversion Price will be subject to adjustment for, among other things, consolidation, reclassification or subdivision of Shares, capitalization of profits or reserves, distributions, rights issue of Shares or options over Shares at less than 95 per cent. of the current market price, rights issues of other securities, issues of Shares or other options over Shares at less than 95 per cent. of the current market price, issues of securities or other options over securities at less than 95 per cent. of the current market price, modification of rights of conversion at less than 95 per cent. of the current market price, other offers to Shareholders and other events as described in the Terms and Conditions.

The Conversion Price shall not in any event be reduced to below the nominal value of the Shares as a result of any adjustment under the Terms and Conditions unless under applicable law then in effect the Bonds may be converted at such reduced Conversion Price into legally issued, fully paid and non-assessable Shares.

Adjustment upon Change of Control:	<p>If a Change of Control (as defined in the Terms and Conditions) shall have occurred, the Company shall give notice of that fact to the Bondholders (the “<b>Change of Control Notice</b>”) within 14 days after it becomes aware of such Change of Control. Following the giving of a Change of Control Notice (with a copy to the trustee and the principal agent of the Bonds), upon any exercise of conversion rights such that the relevant Conversion Date falls within the period of 30 days following the later of (1) the relevant Change of Control and (2) the date on which the Change of Control Notice is given to the Bondholders (such period, the “<b>Change of Control Conversion Period</b>”), the Conversion Price shall be adjusted in accordance with the following formula:</p> $\text{NCP} = \text{OCP} / (1 + (\text{CP} \times (c/t))), \text{ where}$ <p>NCP = the Conversion Price after such adjustment;</p> <p>OCP = the Conversion Price before such adjustment. For the avoidance of doubt, OCP for the purposes of this adjustment shall be the Conversion Price applicable on the relevant Conversion Date in respect of any conversion to which this adjustment is applicable;</p> <p>CP (or Conversion Premium) = 47.00 per cent. expressed as a fraction;</p> <p>c = the number of days from and including the date the Change of Control occurs to but excluding the Maturity Date; and</p> <p>t = the number of days from and including the Issue Date to but excluding the Maturity Date.</p>
Ranking of Conversion Shares:	<p>The Conversion Shares will be fully paid and will in all respects rank <i>pari passu</i> with the fully paid Shares in issue on the relevant registration date except for any right excluded by mandatory provisions of applicable law and except that such Conversion Shares will not rank for (or, as the case may be, the relevant holder shall not be entitled to receive) any rights, distributions or payments the record or other due date for the establishment of entitlement for which falls prior to the relevant registration date.</p>
Redemption at Maturity:	<p>Unless previously redeemed, converted or purchased and cancelled, the Company will redeem each Bond at its principal amount on the Maturity Date.</p>

Redemption for  
Taxation Reasons:

The Company may redeem all and not some only of the Bonds, at its option, at any time, on giving not less than 30 nor more than 60 days' notice (a "**Tax Redemption Notice**") to the trustee or the principal agent of the Bonds in writing and to the Bondholders in accordance with the Terms and Conditions (which notice shall be irrevocable), on the date specified in the Tax Redemption Notice for redemption (the "**Tax Redemption Date**") at its principal amount, if the Company satisfies the trustee of the Bonds immediately prior to the giving of such notice that (a) the Company has or will become obliged to pay additional tax amounts as provided or referred to in the Terms and Conditions as result of any change in, or amendment to, the laws or regulations of the PRC or the Cayman Islands, or, in each case, any political subdivision or any authority thereof or therein having power to tax, or any change in the general application or official interpretation of such laws or regulations, which change or amendment becomes effective on or after January 26, 2026, and (b) such obligation cannot be avoided by the Company taking reasonable measures available to it, provided that no Tax Redemption Notice shall be given earlier than 90 days prior to the earliest date on which the Company would be obliged to pay such additional tax amounts were a payment in respect of the Bonds then due.

If the Company gives a Tax Redemption Notice pursuant to the condition on redemption for taxation reasons, each Bondholder will have the right to elect that his Bond(s) shall not be redeemed and that the provisions on the condition of taxation shall not apply in respect of any payment of principal, premium (if any) or interest (if any) to be made in respect of such Bond(s) which falls due after the relevant Tax Redemption Date, whereupon no additional amounts shall be payable by the Company in respect thereof pursuant to the condition on taxation and payment of all amounts by the Company to such holder in respect of such Bond(s) shall be made subject to the deduction or withholding of any tax required to be deducted or withheld.

Redemption at the Option  
of the Company:

On giving not less than 30 nor more than 60 days' notice (the "**Optional Redemption Notice**") to the trustee or the principal agent of the Bonds in writing, and to the Bondholders in accordance with the Terms and Conditions, the Company may redeem all and not some only of the Bonds on the date (the "**Optional Redemption Date**") specified in the Optional Redemption Notice at their principal amount at any time if, prior to the date the relevant Optional Redemption Notice is given, Conversion Rights shall have been exercised and/or purchases (and corresponding cancellations) and/or redemptions effected in respect of 90 per cent. or more in principal amount of the Bonds originally issued (which shall for this purpose include any further Bonds issued pursuant to the Terms and Conditions).

Redemption for Delisting  
or Change of Control:

Following the occurrence of a Relevant Event, the holder of each Bond will have the right at such holder's option, to require the Company to redeem all or some only of such holder's Bonds on the Relevant Event Put Date at their principal amount. To exercise such right, the holder of the relevant Bond must deposit during normal business hours (being between 9:00 a.m. and 3:00 p.m. on a business day) at the specified office of any paying agent a duly completed and signed notice of redemption, in the form for the time being current, obtainable during normal business hours (being between 9:00 a.m. and 3:00 p.m. on a business day) from the specified office of any paying agent (a "**Relevant Event Put Exercise Notice**"), together with the certificate evidencing the Bonds to be redeemed by not later than 60 days following a Relevant Event, or, if later, 60 days following the date upon which notice thereof is given to Bondholders by the Company in accordance with the Terms and Conditions. The "**Relevant Event Put Date**" shall be the fourteenth day after the expiry of such period of 60 days as referred to above.

A Relevant Event Put Exercise Notice, once delivered, shall be irrevocable and may not be withdrawn without the Company's consent.

Within 14 days after it becomes aware of the occurrence of a Relevant Event, the Company shall give notice thereof to the trustee or the principal agent of the Bonds in writing and to the Bondholders in accordance with the Terms and Conditions. The notice regarding the Relevant Event shall contain a statement informing Bondholders of their entitlement to exercise their conversion rights and their entitlement to exercise their rights to require redemption of their Bonds pursuant to the Terms and Conditions.

Redemption at the Option  
of the Bondholders:

On February 3, 2029 and February 3, 2031 (each an "**Optional Put Date**"), the holder of each Bond will have the right at such holder's option, to require the Company to redeem all or some only of the Bonds of such holder on the relevant Optional Put Date at their principal amount. To exercise such right, the Bondholder must complete, sign and deposit with any paying agent a duly completed and signed notice of redemption ("**Optional Put Exercise Notice**") together with the certificate evidencing the Bonds to be redeemed not earlier than 60 days and not later than 30 days prior to the relevant Optional Put Date.

An Optional Put Exercise Notice, once delivered, shall be irrevocable and may not be withdrawn unless the Company consents in writing to such withdrawal.

## CONVERSION PRICE AND CONVERSION SHARES

The initial Conversion Price is HK\$57.39 per Conversion Share, which represents:

- (a) a premium of approximately 42.62 per cent. over the Closing Price of HK\$40.24 as quoted on the Stock Exchange on January 26, 2026 (being the date which the Subscription Agreement was entered into);
- (b) a premium of approximately 41.80 per cent. over HK\$40.47, being the average of the Closing Price per Share as quoted on the Stock Exchange for the last five consecutive trading days up to and including January 23, 2026; and
- (c) a premium of approximately 38.59 per cent. over HK\$41.41, being the average of the Closing Price per Share as quoted on the Stock Exchange for the last 10 consecutive trading days up to and including January 23, 2026.

The Conversion Price was determined with reference to the prevailing market price of the Shares and the Terms and Conditions (including the redemption options) and was negotiated on an arm's length basis between the Company and the Managers after a book-building exercise. The Directors consider that the Conversion Price is fair and reasonable based on the current market conditions and in the interests of the Company and the Shareholders as a whole.

The Bonds may be converted into Conversion Shares pursuant to the Terms and Conditions. Assuming full conversion of the Bonds at the initial Conversion Price of HK\$57.39 per Share and no further issue of Shares, the Bonds will be convertible into 81,547,308 Shares (with aggregate nominal value of approximately HK\$815), representing approximately 1.35% of the issued share capital of the Company as at the date of this announcement and approximately 1.33% of the issued share capital of the Company as at the date of this announcement as enlarged by the issue of the Conversion Shares upon full conversion of the Bonds. The Conversion Shares to be issued upon conversion of the Bonds will rank *pari passu* and carry the same rights and privileges in all respects with the Shares then in issue on the relevant registration date.

## EFFECT ON SHAREHOLDING STRUCTURE

The following table summarizes the potential effects on the shareholding structure of the Company as a result of the issue of the Bonds (by reference to the information on shareholdings available to the Company as at the date of this announcement and assuming full conversion of the Bonds and no further changes in the share capital of the Company):

Shareholder	As at the date of this announcement		Assuming the Bonds are fully converted into Shares at the initial Conversion Price	
	Number of Shares	Approximate % of issued share capital of the Company	Number of Shares	Approximate % of issued share capital of the Company
– Stellar Infinity Company Ltd.	3,900,000,000	64.41%	3,900,000,000	63.55%
– Apex Medical Company Ltd.	920,000,000	15.19%	920,000,000	14.99%
<i>Directors<sup>(1)</sup></i>	3,948,306	0.07%	3,948,306	0.06%
<i>Public Shareholders</i>				
– The Bondholders	–	–	81,547,308	1.33%
– Other Public Shareholders	1,231,201,764	20.33%	1,231,201,764	20.07%
<b>Total</b>	<b>6,055,150,070</b>	<b>100.00%</b>	<b>6,136,697,378</b>	<b>100.00%</b>

*Note:*

- (1) For the purpose of the above table, the shareholding of Directors only includes the number of Shares held directly by the Directors at the relevant dates.
- (2) The percentage figures included in this table have been subject to rounding adjustment.

## USE OF PROCEEDS

The net proceeds from the Bonds (after deduction of commissions and other related expenses) are estimated to be approximately HK\$4,640 million, representing a net issue price of approximately HK\$56.90 per Conversion Share based on the initial Conversion Price. The Group intends to apply the net proceeds from the issue of the Bonds as follows:

- (a) approximately 65% on drug research and development (“R&D”) and in-licensing: including the R&D of innovative drugs for oncology, central nervous system, metabolic and autoimmune diseases, and in-licensing projects for innovative drugs and innovative R&D platforms;
- (b) approximately 25% on the construction of new R&D centers and production lines, and the upgrade of existing R&D and production facilities: including the construction of innovative drug R&D centers and laboratories, the construction of new production lines and the upgrading of existing R&D laboratories and production workshops; and
- (c) approximately 10% for working capital and other general corporate purposes.

## **REASONS FOR AND BENEFITS OF THE ISSUE OF THE BONDS**

The Directors consider the issue of Bonds represents an opportunity to raise capital for the Company while broadening the shareholder base and capital base of the Company and to obtain immediate funding for further business expansion. The Directors (including the independent non-executive Directors) consider that the terms and conditions of the Subscription Agreement are made on normal commercial terms and are fair and reasonable as far as the Shareholders are concerned, and the issue of the Bonds is in the interests of the Company and the Shareholders as a whole.

## **GENERAL MANDATE**

The Conversion Shares will be allotted and issued under the General Mandate granted to the Directors at the annual general meeting of the Company held on June 20, 2025. Under the General Mandate, a maximum of 1,189,430,014 new Shares may fall to be allotted and issued, representing 20% of the total number of issued shares (excluding any treasury shares) of the Company as at the date of passing of the resolution. As at the date of this announcement, save the issuance of 108,000,000 Shares under the General Mandate pursuant to a placing agreement dated August 20, 2025, no other Shares have been issued or committed to be issued under the General Mandate. Accordingly, as at the date of this announcement, the number of Shares that the Company may issue under the General Mandate is 1,081,430,014. The issue of the Conversion Shares is therefore not subject to additional approval of the Shareholders.

If the number of the Conversion Shares exceeds the General Mandate upon future adjustment to the Conversion Price pursuant to the Terms and Conditions, the Company will seek a specific mandate from its Shareholders for issuing the Conversion Shares exceeding the General Mandate.

## **EQUITY FUND-RAISING ACTIVITY BY THE COMPANY IN THE LAST 12 MONTHS**

The Company has previously conducted a placing of new Shares pursuant to a placing agreement dated August 20, 2025. For further details, please refer to the Company's announcement dated August 20, 2025 (the "**Announcement**"). The net proceeds from the placing (after deducting the placing commission, levies and trading fee) were approximately HK\$3,896.54 million, which have been and will be used in the following manner as disclosed in the Announcement: (i) approximately 65% for (a) the R&D of new innovative drugs in therapeutic areas including oncology, autoimmune, central nervous system and metabolic diseases, and (b) the in-licensing for innovative drugs and innovative technology platforms; (ii) approximately 25% to fund (a) the construction of new innovative drug production facilities and R&D laboratories, and (b) the upgrade of the Group's existing R&D laboratories and production facilities; and (iii) approximately 10% for working capital and other general corporate purposes. The balance is expected to be fully utilized by 2031. As at December 31, 2025, net proceeds of approximately HK\$436 million was utilized and approximately HK\$3,461 million remains unutilized. The net proceeds were used, and the remaining proceeds will be used, according to the intended purposes and timelines previously disclosed by the Company.

Save as disclosed above, the Company has not raised any fund by issuing equity securities during the 12 months immediately before the date of this announcement.

## CONCURRENT DELTA PLACEMENT

Concurrent with the offering of the Bonds, the Managers may facilitate sales of existing Shares notionally underlying the Bonds by buyers of the Bonds who wish to sell such Shares in covered short sales to purchasers procured by the Managers in order to hedge the market risk to which the buyers of the Bonds are exposed with respect to the Bonds that they may acquire in the offering of the Bonds.

## GENERAL INFORMATION

The Company is a leading innovation-driven pharmaceutical enterprise in China. With the mission of “continuous innovation for better life”, the Company focuses on major disease therapeutic areas such as oncology, anti-infectives, central nervous system, metabolism and autoimmunity.

## APPLICATION FOR LISTING

An application will be made to the Vienna MTF operated by the Vienna Stock Exchange for the listing of, and permission to deal in, the Bonds. The Company will also apply to the Stock Exchange for the listing of, and permission to deal in, the Conversion Shares on the Stock Exchange.

**Completion of the transactions under the Subscription Agreement is subject to the satisfaction and/or waiver of certain conditions precedent therein. As the issue of the Bonds under the Subscription Agreement may or may not proceed to completion, and the Bonds and/or the Conversion Shares may or may not be issued or listed, Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.**

## DEFINITIONS

In this announcement, the following expressions have the following meanings unless the context requires otherwise:

“Agency Agreement”	the paying, conversion and transfer agency agreement in respect of the Bonds to be entered into among the Company, the trustee of the Bonds and the other agents named therein
“Board”	the board of Directors
“Bondholders”	holders of the Bonds from time to time
“Bonds”	the zero coupon convertible bonds due 2033 in an aggregate principal amount of HK\$4,680 million to be issued by the Company pursuant to the Subscription Agreement

“Closing Date” or the “Issue Date”	the date on which the Bonds are issued, which is tentatively scheduled for February 3, 2026 or such later date (not being later than February 17, 2026) as the Company and the Managers may agree
“Closing Price”	for the Shares for any trading day, the price of which is published in the daily quotation sheet published by the Stock Exchange
“Company”	Hansoh Pharmaceutical Group Company Limited (翰森製藥集團有限公司), a company incorporated in the Cayman Islands with limited liability on December 2, 2015
“connected person”	has the meaning given to it in the Listing Rules
“Contracts”	the Trust Deed, the Agency Agreement and the Subscription Agreement
“Conversion Shares”	the Shares to be issued by the Company upon conversion of the Bonds pursuant to the Trust Deed and the Terms and Conditions
“Directors”	the directors of the Company
“General Mandate”	the general mandate to allot and issue Shares granted to the Directors
“Group”	the Company and its subsidiaries
“HK\$”	Hong Kong dollars, the lawful currency of Hong Kong
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited
“Managers”	Morgan Stanley Asia Limited and Citigroup Global Markets Limited
“Maturity Date”	means February 3, 2033
“NDRC”	the National Development and Reform Commission of the PRC
“PRC”	the People’s Republic of China, excluding for the purpose of this announcement, Hong Kong, Macau Special Administrative Region and Taiwan

“professional investors”	has the meaning given to it in the Securities and Futures Ordinance (Cap. 571) and the Securities and Futures (Professional Investors) Rules (Cap. 571D)
“Relevant Event”	when the Shares cease to be listed or admitted to trading or are suspended from trading on the Main Board of the Stock Exchange for a period equal to or exceeding 30 consecutive trading days, or when there is a change of control
“Restricted Share Unit Scheme”	the restricted share unit scheme adopted by the Company as disclosed in the prospectus dated May 31, 2019 issued by the Company
“Shareholders”	holders of the Shares
“Share(s)”	ordinary share(s) in the capital of the Company having a par value of HK\$0.00001
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Subscription Agreement”	the agreement dated January 26, 2026 entered into between the Company and the Managers in relation to the subscription of the Bonds
“Terms and Conditions”	the terms and conditions of the Bonds
“Trust Deed”	the trust deed constituting the Bonds to be entered into between the Company and the trustee of the Bonds
“United States”	the United States of America
“%”	percentage

By Order of the Board  
**Hansoh Pharmaceutical Group Company Limited**  
**Zhong Huijuan**  
*Chairlady*

Hong Kong, January 27, 2026

*As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive director, Ms. Sun Yuan and Dr. Lyu Aifeng as executive directors, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai, Ms. Yang Dongtao and Mr. Yan Jia as independent non-executive directors.*